- Home
- FANG vs ALNY Comparison
FANG vs ALNY Comparison
Compare FANG & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FANG
- ALNY
- Stock Information
- Founded
- FANG 2007
- ALNY 2002
- Country
- FANG United States
- ALNY United States
- Employees
- FANG N/A
- ALNY N/A
- Industry
- FANG Oil & Gas Production
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- FANG Energy
- ALNY Health Care
- Exchange
- FANG Nasdaq
- ALNY Nasdaq
- Market Cap
- FANG 41.2B
- ALNY 39.6B
- IPO Year
- FANG 2012
- ALNY 2004
- Fundamental
- Price
- FANG $148.85
- ALNY $309.70
- Analyst Decision
- FANG Strong Buy
- ALNY Strong Buy
- Analyst Count
- FANG 21
- ALNY 25
- Target Price
- FANG $195.19
- ALNY $324.96
- AVG Volume (30 Days)
- FANG 2.6M
- ALNY 849.2K
- Earning Date
- FANG 08-04-2025
- ALNY 07-31-2025
- Dividend Yield
- FANG 3.52%
- ALNY N/A
- EPS Growth
- FANG N/A
- ALNY N/A
- EPS
- FANG 16.37
- ALNY N/A
- Revenue
- FANG $12,286,000,000.00
- ALNY $2,348,099,000.00
- Revenue This Year
- FANG $37.61
- ALNY $30.77
- Revenue Next Year
- FANG N/A
- ALNY $30.51
- P/E Ratio
- FANG $9.10
- ALNY N/A
- Revenue Growth
- FANG 46.77
- ALNY 17.21
- 52 Week Low
- FANG $114.00
- ALNY $153.23
- 52 Week High
- FANG $214.50
- ALNY $317.54
- Technical
- Relative Strength Index (RSI)
- FANG 57.43
- ALNY 63.60
- Support Level
- FANG $148.83
- ALNY $295.82
- Resistance Level
- FANG $156.03
- ALNY $317.54
- Average True Range (ATR)
- FANG 4.60
- ALNY 7.74
- MACD
- FANG 0.85
- ALNY -0.67
- Stochastic Oscillator
- FANG 58.67
- ALNY 63.90
About FANG Diamondback Energy Inc.
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2024, the company reported net proven reserves of 3.6 billion barrels of oil equivalent. Net production averaged about 598,000 barrels per day in 2024, at a ratio of 56% oil, 23% natural gas liquids, and 21% natural gas.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.